Cuprina provides update on research studies on three education institutes

Cuprina Holdings (CUPR) provided an update on progress achieved in relation to three studies carried out with institutes of higher learning. The studies, each one year in length, were aimed at helping Cuprina and these institutes jointly produce collagen peptide molecules derived from American bullfrog skin. These peptides, as well as their short chain variants, are widely considered to be useful in the manufacture of an array of medical, pharmaceutical, nutraceutical and cosmetic products. The first study was performed pursuant to a consultancy proposal signed in February 2024 with Republic Polytechnic. Since the completion of this consultancy proposal in February 2025, Cuprina has identified a method to generate a series of these peptides that can potentially be used for cosmeceutical applications including skin moisturization, collagen remodeling, and other commercial applications. Cuprina’s second study, a research collaboration agreement which commenced in October 2024, was signed with the Institute for Health Innovation and Technology at the National University of Singapore. Currently, Cuprina is performing testing aimed at measuring the effect of integrating bullfrog collagen into the structure of microneedling patches, which contain tiny needles that allow active ingredients to penetrate deeper into the skin and enhance wound healing. The third study is an RCA with the Singapore Institute of Technology, an autonomous university in Singapore, that commenced in January 2025